Akari Therapeutics, Plc
NASDAQ Capital MarketTotal Valuation
Akari Therapeutics, Plc carries a market capitalization of 13.13M, placing it among publicly traded companies globally.
| Market Cap | 13.13M |
| Enterprise Value | N/A |
Share Statistics
Akari Therapeutics, Plc currently has 91.57B shares outstanding.
| Shares Outstanding | 91.57B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 32,793.47 |
| P/TBV Ratio | -29,621.24 |
| P/FCF Ratio | -0.49 |
| P/OCF Ratio | -0.49 |
Financial Position
Akari Therapeutics, Plc maintains a current ratio of 0.27, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.27 |
| Quick Ratio | 0.21 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -12.77 |
Financial Efficiency
| Return on Equity (ROE) | -155.28 |
| Return on Assets (ROA) | -66.11 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -1.86M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Akari Therapeutics, Plc's stock has declined approximately -64.9771% over the past 52 weeks. The 50-day moving average sits at 9.56, while the 200-day moving average is 9.95.
| Beta (5Y) | N/A |
| 52-Week Price Change | -64.9771% |
| 50-Day Moving Average | 9.56 |
| 200-Day Moving Average | 9.95 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -12.20M, while operating income came in at -12.20M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -12.20M |
| Pretax Income | -29.91M |
| Net Income | -28.05M |
| EBITDA | -12.20M |
| EBIT | -12.20M |
| Earnings Per Share (EPS) | -27.25 |
Balance Sheet
Total book value stands at 14.38M, with working capital of -9.83M providing operational flexibility.
| Cash & Cash Equivalents | 2.77M |
| Total Debt | N/A |
| Net Debt | -2.04M |
| Equity (Book Value) | 14.38M |
| Book Value Per Share | 0.00 |
| Working Capital | -9.83M |
Cash Flow
Akari Therapeutics, Plc produced -10.91M in operating cash flow over the past twelve months.
| Operating Cash Flow | -10.91M |
| Capital Expenditures | N/A |
| Free Cash Flow | -10.91M |
| FCF Per Share | -10.60 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.00 |
| FCF Yield | -205.74 |
Stock Splits
Akari Therapeutics, Plc's most recent stock split took place on March 31, 2026 with a 40:1 split ratio.
| Last Split Date | 3/31/2026 |
| Split Ratio | 40:1 |
Scores
Akari Therapeutics, Plc posts an Altman Z-Score of 14,379.82, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 14,379.82 |